RMMS Shortlisted for the “Firm of the Year - Life Sciences IP Litigation” by Managing Intellectual Property 03/08/2023
RMMS Receives Continued Recognition in IAM Patent 1000 – Two Firm Partners Individually Ranked 07/06/2022
RMMS Again Recognized by Chambers & Partners – RMMS, William Rakoczy Ranked Nationally for Life Sciences 06/03/2022
Federal Circuit Affirms Judgment Involving DUEXIS® Tablets (800 mg ibuprofen and 26.6 mg famotidine 11/16/2021
RMMS Secures Non-Infringement and Invalidity Win on BROMSITE® (bromfenac ophthalmic solution) 0.075% 10/01/2021
RMMS Partner Tara M. Raghavan Installed as President-Elect of the South Asian Bar Association of North America 07/21/2021
RMMS Receives Continued Recognition in IAM Patent 1000 – Five Firm Partners Individually Ranked 07/02/2021
RMMS Ranked Nationally for Life Sciences IP - Paul Molino & William Rakoczy Again Recognized as IP Stars 06/18/2021
RMMS Again Recognized by Chambers & Partners - William Rakoczy Ranked Nationally for Life Sciences 05/24/2021
RMMS Scores Win in Case Involving DUEXIS® tablets (800 mg ibuprofen and 26.6 mg famotidine) 11/30/2020
RMMS Again Recognized as Litigation Leader in IAM Patent 1000 – Firm Partners Receive Individual Recognition 06/11/2020
RMMS Secures Favorable Resolution in BPCIA Litigation Involving FULPHILA® (pegfilgrastim-jmdb) 11/01/2019
RMMS Recognized as Litigation Leader in IAM Patent 1000 - William Rakoczy and Deanne Mazzochi Receive Individual Recognition 06/10/2019
RMMS Recognized Nationally and Regionally for Life Sciences Litigation - William Rakoczy and Paul Molino Selected as IP Stars 04/02/2019
RMMS Files Supreme Court Amicus Brief on Behalf of AAM Challenging The Federal Circuit’s Reading Of The IPR Time Bar Under Section 315(b) 02/13/2019
RMMS Secures Favorable Claim Construction Ruling in NEULASTA® (pegfilgrastim) BPCIA Litigation 11/20/2018
RMMS Listed as Highly Recommended Patent Firm by Managing IP; William A. Rakoczy and Paul J. Molino Recognized as IP Stars 06/22/2018
RMMS Partner Deanne M. Mazzochi Recognized as a Top Lawyer among Leading Women Lawyers in Illinois by Leading Lawyers 06/22/2018
RMMS Recognized as a Leading Patent Firm in Litigation by IAM Patent 1000; William A. Rakoczy Individually Ranked “Gold” in Litigation by IAM Patent 1000 06/22/2018
Federal Circuit Affirms Invalidity Judgment Concerning AXIRON® (Testosterone) Transdermal Solution 11/22/2017
Federal Circuit Affirms Collateral Estoppel Decision Concerning Latisse® (bimatoprost topical solution) 03/17/2017
RMMS Secures Invalidity And Non-Infringement Victories on Patents Related To Axiron® (Testosterone) Transdermal Solution 08/22/2016
Federal Circuit Affirms Judgment of Invalidity Concerning OxyContin® (oxycodone extended-release tablets) 02/01/2016
RMMS Secures Favorable Claim Construction Ruling In Suit Involving Generic Aripiprazole (Abilify®) 11/16/2015
Federal Circuit Affirms Judgment of Invalidity Concerning Pulmicort Respules® (budesonide inhalation suspension) 05/07/2015
Federal Circuit Affirms Invalidity Judgment Concerning Zymaxid®/Zymar® (Gatifloxacin) Ophthalmic Solutions 03/20/2015
RMMS Files Supreme Court Amicus Brief on Behalf of GPhA Supporting Specific-Intent-to-Infringe Requirement for Induced Infringement 02/26/2015
RMMS Secures Judgment of Patent Invalidity Following Remand Trial Involving Generic Pulmicort Respules® (Budesonide Inhalation Suspension) 02/13/2015
Federal Circuit Affirms Judgment Of Non-Infringement Involving Generic Trizivir® (Abacavir Sulfate, Lamivudine, and Zidovudine) Tablets 02/12/2015
RMMS Secures Reversal Before Federal Circuit, Invalidating Asserted Patents Concerning Latisse® (bimatoprost) Ophthalmic Solution 07/10/2014
U.S. Court Of Appeals For The Federal Circuit Affirms RMMS's Victory Involving Generic Ibandronate Products 04/11/2014
RMMS Secures Judgment Of Non-Infringement After A Trial Involving Generic Trizivir® (Abacavir Sulfate; Lamivudine; Zidovudine) Tablets 12/17/2013
rmms-secures-judgment-of-patent-invalidity-after-a-trial-involving-gatifloxacin-ocular-formulation-and-method 08/09/2013
Federal Circuit Affirms Judgment Of Non-Infringement Involving Generic Mometasone Furoate Nasal Spray 06/10/2013
RMMS Secures Judgment Of Patent Invalidity And Non-Infringement After A Trial Involving Budesonide Inhalation Suspension 04/01/2013
RMMS Defeats Motion for Preliminary Injunction Involving Generic Tiagabine Hydrochloride Products 12/20/2012
RMMS LLP recognized as one of the top Hatch-Waxman litigation firms in the country by LMG Life Sciences 06/16/2012
RMMS Secures Judgment Of Non-Infringement After A Trial Involving Generic Mometasone Furoate Nasal Spray 06/15/2012
RMMS Secures Summary Judgment of Non-Infringement Involving Generic Guaifenesin Extended-Release Tablets, 600 mg 01/11/2012
RMMS Defeats Motion for Preliminary Injunction Involving Generic Carbamazepine Extended-Release Capsules 07/06/2011
RMMS Secures Federal Circuit Ruling Affirming Trial Decision of Patent Invalidity Involving Generic Galantamine 09/25/2009
RMMS Defeats Motion for Temporary Restraining Order Involving Generic Piperacillin/Tazobactam Injections 09/24/2009
RMMS Secures Federal Circuit En Banc Ruling Affirming Summary Judgment Of Noninfringement Involving Generic Cefdinir 05/19/2009
RMMS Defeats Motion for Temporary Restraining Order and Preliminary Injunction Involving Generic Ramipril Capsules 06/10/2008
RMMS Defeats Motion for Preliminary Injunction Involving Generic Clobetasol Propionate Foam Products 03/19/2008
RMMS Wins Summary Judgment of Non-Infringement for Generic Client in Patent Dispute Involving Pfizer's Blockbuster Prescription Drug Neurontin® 08/22/2005
RMMS Wins Summary Judgment of Non-Infringement for Generic Client in Patent Dispute Involving Pfizer's Blockbuster Prescription Drug Neurontin® 08/22/2005
